Evidence map›Paper›PMID 41097734›Full record

ArticleCancers2025

VSIG4 Is Dispensable for Tumor Growth and Metastasis in Murine Colorectal and Breast Cancer Models.

Els Lebegge, Neema Ahishakiye Jumapili, Jolien Van Craenenbroeck, Daliya Kancheva, Máté Kiss, Romina Mora Barthelmess, Ahmed E I Hamouda, Yvon Elkrim, Geert Raes, Éva Hadadi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Els LebeggeLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Neema Ahishakiye JumapiliLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.ORCID 0000-0003-3663-733X
Jolien Van CraenenbroeckLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Daliya KanchevaLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Máté KissLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Romina Mora BarthelmessLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Ahmed E I HamoudaLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.ORCID 0000-0001-6532-9585
Yvon ElkrimLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Geert RaesLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.ORCID 0000-0002-9065-1549
Éva HadadiLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Damya LaouiLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.ORCID 0000-0002-3373-1403
Jo A Van GinderachterLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.ORCID 0000-0002-4442-7474
Sana M ArnoukLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.

Funding

Fonds voor Wetenschappelijk Onderzoek 1S67419NFonds voor Wetenschappelijk Onderzoek-strategic basic research S000218NKom Op Tegen Kanker N.A.
6 · The paper itself

Abstract

backgroundTumor-associated macrophages (TAMs) are important contributors to tumor progression and metastasis. Therefore, the identification of molecules that mediate these cells' tumor-promoting functions is highly warranted. VSIG4 has been proposed as a macrophage immune checkpoint. Hence, we aim to investigate this marker in preclinical models.

methodsPublicly available scRNAseq datasets of human colorectal (CRC) and triple-negative breast (TNBC) carcinomas and their murine counterparts were reanalyzed to investigate the expression of VSIG4 in the different TAM populations. Moreover, tumors were grown in

resultsWe demonstrate that

conclusionsMurine cancer models are not suitable to investigate the role of VSIG4 in primary tumors and VSIG4 deficiency did not alter liver nor peritoneal cavity metastasis in murine models, with the exception of the omentum.

Indexed as

cancercolorectal carcinomaKupffer cellslarge peritoneal macrophagestriple negative breast cancertumor-associated macrophagestumor microenvironmentVSIG4

Identifiers

PMID41097734
PMCPMC12523294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.